Overview
- Consolidated revenue rose about 9% year-on-year to Rs 14,478 crore, with EBITDA up 14.9% to Rs 4,527 crore and margin at 31.3%, while PAT increased 2.6% to Rs 3,117.95 crore.
- In the U.S., innovative medicines revenue exceeded generics for the first time, supported by the launch of Leqselvi for severe alopecia areata.
- Global Innovative Medicines sales reached $333 million, up 16.4% and contributing roughly one-fifth of consolidated revenue.
- India formulations grew 11% to Rs 4,734.8 crore with nine launches, and the quarter saw four ANDA filings, five ANDA approvals and one NDA filing, with 57 approved NDAs and 14 pending at the US FDA.
- External API sales fell 19.5% year-on-year to Rs 4,299 million, while Macquarie, Citi and Morgan Stanley reiterated positive views and raised or maintained targets citing resilient margins and portfolio strength.